As part as of vivitide’s commitment to providing relevant information to researchers, we present our latest version of The COVID-19 Information Station.   It features daily updates to coronavirus related news sorted by research topics and date, relevant product literature, and a list of dozens of pertinent products, many just added in just the last week!

Some of the recently added items include the following:


This inhibitor for SARS-CoV-2 Main Protease (Mpro, a.k.a. 3CLpro) is referenced in a new paper by researchers principally from the Wroclaw University of Science and Technology in Poland and the Institute of Molecular Medicine, University of Lübeck, Germany.

As they stated, they “focused on the SARS-CoV-2 main protease that constitutes one of the most attractive antiviral drug targets.”  After synthesizing a combinatorial library of fluorogenic substrates with glutamine in the P1 position, they then determined the protease preference and synthesized this potent SARS-CoV-2 inhibitor (Ac-Abu-dTyr-Leu-Gln-VS).1

In addition to the inhibitor, we have a plethora of new SAR-CoV-2 proteins, included spike segments and nucleocapsids.

CoV-2-Spike (1-1211)
CoV-2 N (329 a.a.)
CoV-2 S1 (319-529)

For these and dozens of other substrates, proteins, and peptides, we urge you to visit The COVID-19 Information Station.  

If you have need of a custom peptide synthesis, please visit our Custom Peptide Synthesis Services offerings.

Antibodies to spike protein or ACE2 may also block important binding interactions and prevent infection. For more information on vivitide’s Custom Antibody development, please visit:

W. Rut, et. al, Nat. Chem. Biol., in press .(Original)